AUS
NZ
UK
CA
USA
IND
Highlights
Total revenues reached US$20.7 million for Q2 2025, up 9.6% year-over-year.
Net loss narrowed to US$1.4 million from US$108.0 million in Q2 2024.
Operating expenses decreased 42.1% to US$16.7 million due to efficiency measures.
Burning Rock Biotech Limited (NASDAQ:BNR) reported total revenues of RMB148.5 million (US$20.7 million) for the three months ended June 30, 2025, representing a 9.6% increase from RMB135.5 million in the same period of 2024.
Revenue from the in-hospital business was RMB62.5 million (US$8.7 million), up 4.4% from RMB59.9 million a year earlier, driven by increased sales volumes at existing hospitals and newly contracted partners. Central laboratory business revenue decreased 16.2% to RMB40.9 million (US$5.7 million), reflecting a decline in test volume as the company continues its shift toward in-hospital testing. Revenue from pharma research and development services grew 68.1% to RMB45.2 million (US$6.3 million) due to expanded testing and development services for pharmaceutical clients.
Gross Profit and Margins
Gross profit for Q2 2025 reached RMB108.1 million (US$15.1 million), up 13.3% from RMB95.4 million in the prior-year period, with a gross margin of 72.8%, compared to 70.4% in Q2 2024. By segment, central laboratory business reported a gross margin of 87.9%, in-hospital business 74.4%, and pharma R&D services 56.8%. Non-GAAP gross profit, excluding depreciation and amortization, was RMB110.5 million (US$15.4 million), representing an 8.4% increase from Q2 2024, with a non-GAAP gross margin of 74.4%.
Operating Expenses and Net Loss
Operating expenses for the quarter were RMB119.6 million (US$16.7 million), down 42.1% from RMB206.7 million in Q2 2024, reflecting budget controls and headcount reductions. Research and development expenses fell 23.4% to RMB49.8 million (US$6.9 million), driven by lower amortized share-based compensation and decreased project expenditures. Selling and marketing expenses declined 21.5% to RMB38.4 million (US$5.4 million), while general and administrative expenses decreased 66.1% to RMB31.4 million (US$4.4 million).
As a result, net loss narrowed significantly to RMB9.7 million (US$1.4 million) from RMB108.0 million in Q2 2024.
Liquidity Position
Cash, cash equivalents, and restricted cash totaled RMB455.0 million (US$63.5 million) as of June 30, 2025, providing resources to support ongoing operations and business development.
About Burning Rock Biotech
Burning Rock Biotech focuses on the application of next-generation sequencing (NGS) in precision oncology. Its operations include NGS-based therapy selection testing for late-stage cancer patients and cancer early detection, which has progressed into clinical validation. The company’s mission is to advance life-saving science and improve outcomes in cancer care.
